---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004554"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:19:16.075868+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health: initial REVEAL-1 data show weight maintenance post-GLP-1 discontinuation; REMAIN-1 enrollment strong

## Summary
- First REVEAL-1 patient achieved 15% total body weight loss on tirzepatide, then maintained weight 1 month after Revita post-discontinuation.
- Prior studies show average 3% weight regain within 4 weeks of GLP-1 discontinuation, highlighting Revita potential.
- Over 100 patients enrolled across 8 sites in REMAIN-1 study in less than 4 months; high demand.
- REVEAL-1 cohort data presentation delayed to Q1 2025 due to holiday scheduling; mid-point analysis expected Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-004554
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017025004554/0000950170-25-004554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017025004554/guts-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004554
- JSON: https://secwatch.observer/filing/0000950170-25-004554.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004554.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.